Company intelligence / Profile preview
Oryzon Genomics
Cornellà de Llobregat, Catalonia, Spainoryzon.com ↗
- Ownership
- Public · ORY
- Employees
- ~46
- Development stage
- Other
01
Overview
Oryzon has advanced two selective LSD1 inhibitors into Phase II clinical trials: iadademstat for oncology indications such as AML and SCLC; vafidemstat optimized for CNS indications with multiple ongoing or completed Phase II studies in psychiatric and neurological conditions. The company also has a preclinical program ORY‑3001 targeting non-oncological diseases[4][5].
- Therapeutic areas
- OncologyNeurology
- Modalities
- Small molecule inhibitors targeting epigenetic enzymes, specifically LSD1 inhibitorsEpigenetics-based therapeutics
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Financials
- Market cap
- $216.7M
- Total revenue
- $0
- Enterprise value
- $206.8M
Beyond the preview
Go deeper on Oryzon Genomics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oryzon Genomics.